JP2003514872A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003514872A5 JP2003514872A5 JP2001539483A JP2001539483A JP2003514872A5 JP 2003514872 A5 JP2003514872 A5 JP 2003514872A5 JP 2001539483 A JP2001539483 A JP 2001539483A JP 2001539483 A JP2001539483 A JP 2001539483A JP 2003514872 A5 JP2003514872 A5 JP 2003514872A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine composition
- adjuvant
- immunogenic
- conjugate
- negatively charged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000002163 immunogen Effects 0.000 description 21
- 229960005486 vaccine Drugs 0.000 description 19
- 239000002671 adjuvant Substances 0.000 description 18
- 241000711549 Hepacivirus C Species 0.000 description 9
- 108010076039 Polyproteins Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 150000002327 glycerophospholipids Chemical class 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16665299P | 1999-11-19 | 1999-11-19 | |
| US60/166,652 | 1999-11-19 | ||
| US22436200P | 2000-08-11 | 2000-08-11 | |
| US60/224,362 | 2000-08-11 | ||
| PCT/AU2000/001410 WO2001037869A1 (en) | 1999-11-19 | 2000-11-17 | Vaccine compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003514872A JP2003514872A (ja) | 2003-04-22 |
| JP2003514872A5 true JP2003514872A5 (https=) | 2007-11-01 |
Family
ID=26862451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001539483A Ceased JP2003514872A (ja) | 1999-11-19 | 2000-11-17 | ワクチン組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20040191270A1 (https=) |
| EP (1) | EP1239876B1 (https=) |
| JP (1) | JP2003514872A (https=) |
| KR (1) | KR100875483B1 (https=) |
| AT (1) | ATE402715T1 (https=) |
| AU (1) | AU772617B2 (https=) |
| CA (1) | CA2391843C (https=) |
| DE (1) | DE60039715D1 (https=) |
| ES (1) | ES2311478T3 (https=) |
| HK (1) | HK1047892B (https=) |
| NZ (2) | NZ520976A (https=) |
| WO (1) | WO2001037869A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| WO2000048630A1 (en) * | 1999-02-17 | 2000-08-24 | Csl Limited | Immunogenic complexes and methods relating thereto |
| CA2389206C (en) * | 1999-10-27 | 2011-01-04 | Chiron Corporation | Activation of hcv-specific t cells |
| CZ20033515A3 (cs) * | 2001-06-29 | 2005-01-12 | Chiron Corporation | Kompozice vakcíny HCV E1E2 |
| CA2471092A1 (en) * | 2001-12-21 | 2003-07-10 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
| DK1471936T3 (da) * | 2002-01-14 | 2010-04-26 | Novartis Vaccines & Diagnostic | HIV-Vaccine og fremgangsmåde til anvendelse |
| AU2003299994A1 (en) * | 2002-12-27 | 2004-07-29 | Chiron Corporation | Immunogenic compositions containing phospholpid |
| EP1613647A2 (en) * | 2003-04-11 | 2006-01-11 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Use of hcv proteins |
| KR100958505B1 (ko) * | 2004-07-18 | 2010-05-17 | 씨에스엘 리미티드 | 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제 |
| CU23496A1 (es) * | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
| US20070190072A1 (en) * | 2004-09-30 | 2007-08-16 | Csl Limited Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus adjuvant |
| CN102614510A (zh) * | 2004-10-18 | 2012-08-01 | 全球免疫股份有限公司 | 基于酵母的对慢性丙型肝炎感染的治疗 |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| EP2200638B1 (en) * | 2007-10-09 | 2016-03-16 | The University of Melbourne | Compositions for the transfection of cells |
| NZ583377A (en) * | 2007-10-12 | 2013-11-29 | Csl Ltd | Method of eliciting an immune response against pandemic influenza virus |
| JP2012503011A (ja) | 2008-09-19 | 2012-02-02 | グローブイミューン，インコーポレイテッド | 慢性ｃ型肝炎ウイルス感染の免疫療法 |
| WO2010115229A1 (en) | 2009-04-09 | 2010-10-14 | The University Of Melbourne | Immunogenic composition and uses thereof |
| US9555093B2 (en) | 2010-04-30 | 2017-01-31 | Temasek Life Sciences Laboratory Limited | Universal vaccine against H5N1 lineages |
| DK2618842T3 (da) | 2010-09-22 | 2019-07-01 | Ena Therapeutics Pty Ltd | Hidtil ukendt immunstimulerende fremgangsmåde |
| CN104324373B (zh) * | 2010-11-26 | 2018-10-09 | 麦克法兰博尼特医学健康研究公司 | 组合物及其制备方法 |
| CU24112B1 (es) * | 2012-11-05 | 2015-08-27 | Ct De Ingeniería Genética Y Biotecnología | Antígenos vacunales quiméricos contra el virus de la hepatitis c |
| JP5931113B2 (ja) * | 2014-04-08 | 2016-06-08 | ザ ユニバーシティー オブ メルボルン | 免疫原性組成物およびその使用 |
| CN106749672B (zh) * | 2016-11-18 | 2020-06-30 | 江西农业大学 | 一种丙型肝炎病毒融合抗原蛋白及其应用 |
| EP3728289B1 (en) | 2017-12-21 | 2025-09-10 | Axelia Oncology Pty Ltd | Optimised compounds |
| KR20220050873A (ko) | 2019-06-26 | 2022-04-25 | 악셀리아 온콜로지 피티와이 리미티드 | 신규한 분자 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8205892D0 (sv) * | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US5897873A (en) * | 1984-04-12 | 1999-04-27 | The Liposome Company, Inc. | Affinity associated vaccine |
| US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5583112A (en) * | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
| WO1990001948A1 (en) * | 1988-08-25 | 1990-03-08 | The Liposome Company, Inc. | Influenza vaccine and novel adjuvants |
| NZ230747A (en) * | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| US5178860A (en) * | 1989-09-01 | 1993-01-12 | Coopers Animal Health Limited | Adjuvant complexes and vaccine made therefrom |
| US4981684A (en) * | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
| AU643141B2 (en) * | 1991-03-15 | 1993-11-04 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5273965A (en) * | 1992-07-02 | 1993-12-28 | Cambridge Biotech Corporation | Methods for enhancing drug delivery with modified saponins |
| US5650398A (en) * | 1992-07-02 | 1997-07-22 | Cambridge Biotech Corporation | Drug delivery enhancement via modified saponins |
| ATE281526T1 (de) * | 1993-05-05 | 2004-11-15 | Common Services Agency | Hepatitis-c virus typ 4,5 und 6 |
| JPH08510240A (ja) * | 1993-05-12 | 1996-10-29 | カイロン コーポレイション | Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ |
| US5451569A (en) * | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030050263A1 (en) * | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
| BR9506059A (pt) * | 1994-07-29 | 1997-10-28 | Innogenetics Nv | Proteinas envelopes purificadas de virus c para uso de diagnóstico e terapêutico |
| AUPM873294A0 (en) * | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| AU686891B2 (en) * | 1994-10-12 | 1998-02-12 | Iscotec A.B. | Saponin preparations and use thereof in iscoms |
| GB9620795D0 (en) * | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
| GB9513261D0 (en) * | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| SE9600648D0 (sv) * | 1996-02-21 | 1996-02-21 | Bror Morein | Receptorbimdande enhet |
| US6231859B1 (en) * | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
| US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6080725A (en) * | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| BR9809149A (pt) * | 1997-05-20 | 2000-08-01 | Galenica Pharmaceuticals Inc | Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória |
| AU7690898A (en) * | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
| GB9718901D0 (en) * | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| ES2298316T3 (es) * | 1997-09-05 | 2008-05-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
| US20050031638A1 (en) * | 1997-12-24 | 2005-02-10 | Smithkline Beecham Biologicals S.A. | Vaccine |
| PT1077722E (pt) * | 1998-05-22 | 2006-12-29 | Coley Pharm Group Inc | Produtos e composições para utilização na indução da imunidade mucosal |
| US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
| GB9817052D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| US7049302B1 (en) * | 1998-08-10 | 2006-05-23 | Antigenics Inc. | Compositions of CPG and saponin adjuvants and uses thereof |
| FR2783170B1 (fr) * | 1998-09-11 | 2004-07-16 | Pasteur Merieux Serums Vacc | Emulsion immunostimulante |
| WO2000048630A1 (en) * | 1999-02-17 | 2000-08-24 | Csl Limited | Immunogenic complexes and methods relating thereto |
| US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
| CA2389206C (en) * | 1999-10-27 | 2011-01-04 | Chiron Corporation | Activation of hcv-specific t cells |
| US6986892B1 (en) * | 1999-11-24 | 2006-01-17 | Chiron Corporation | Immunogenic Hepatitis C virus non-structural polypeptides |
| FR2814958B1 (fr) * | 2000-10-06 | 2003-03-07 | Aventis Pasteur | Composition vaccinale |
| US7713942B2 (en) * | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
| JP2005519990A (ja) * | 2001-10-12 | 2005-07-07 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物 |
| CA2471092A1 (en) * | 2001-12-21 | 2003-07-10 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
| US8153141B2 (en) * | 2002-04-04 | 2012-04-10 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
| US7196892B2 (en) * | 2002-04-10 | 2007-03-27 | Caelin Gabriel | Method and apparatus for isolating RFI, EMI, and noise transients in power supply circuits |
| PT2241325E (pt) * | 2002-10-29 | 2012-04-12 | Coley Pharm Gmbh | Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c |
| DE602004028468D1 (de) * | 2003-06-17 | 2010-09-16 | Mannkind Corp | Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke |
| BRPI0411514A (pt) * | 2003-06-20 | 2006-08-01 | Coley Pharm Gmbh | antagonistas de receptor toll-like de molécula pequena |
| US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
| CA2536139A1 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
| US20050215501A1 (en) * | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| CA2574090A1 (en) * | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
| KR100958505B1 (ko) * | 2004-07-18 | 2010-05-17 | 씨에스엘 리미티드 | 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제 |
| US20070190072A1 (en) * | 2004-09-30 | 2007-08-16 | Csl Limited Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus adjuvant |
| EP1874325A2 (en) * | 2005-04-08 | 2008-01-09 | Coley Pharmaceutical Group, Inc. | Methods for treating infectious disease exacerbated asthma |
| CN101522213A (zh) * | 2006-09-01 | 2009-09-02 | Csl有限公司 | 引起或诱导免疫应答的方法 |
-
2000
- 2000-11-17 EP EP00975681A patent/EP1239876B1/en not_active Expired - Lifetime
- 2000-11-17 ES ES00975681T patent/ES2311478T3/es not_active Expired - Lifetime
- 2000-11-17 NZ NZ520976A patent/NZ520976A/en not_active IP Right Cessation
- 2000-11-17 HK HK03100096.0A patent/HK1047892B/en not_active IP Right Cessation
- 2000-11-17 JP JP2001539483A patent/JP2003514872A/ja not_active Ceased
- 2000-11-17 DE DE60039715T patent/DE60039715D1/de not_active Expired - Lifetime
- 2000-11-17 NZ NZ518999A patent/NZ518999A/xx not_active IP Right Cessation
- 2000-11-17 AT AT00975681T patent/ATE402715T1/de not_active IP Right Cessation
- 2000-11-17 AU AU13730/01A patent/AU772617B2/en not_active Ceased
- 2000-11-17 CA CA2391843A patent/CA2391843C/en not_active Expired - Fee Related
- 2000-11-17 WO PCT/AU2000/001410 patent/WO2001037869A1/en not_active Ceased
- 2000-11-17 KR KR1020027006431A patent/KR100875483B1/ko not_active Expired - Fee Related
-
2003
- 2003-07-21 US US10/622,470 patent/US20040191270A1/en not_active Abandoned
-
2009
- 2009-11-05 US US12/612,992 patent/US20100047271A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003514872A5 (https=) | ||
| AU722647B2 (en) | Protein-lipid vesicles and autogenous vaccine comprising the same | |
| JP5854559B2 (ja) | 小胞を調製する方法及びこれから製造される製剤 | |
| US5876721A (en) | Vaccines | |
| EP2040745B1 (en) | Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails | |
| WO1992019267A1 (en) | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them | |
| JP2002513773A (ja) | アジュバント組成物及びその使用法 | |
| AU689505B2 (en) | Protein- or peptide-cochleate vaccines and methods of immunizing using the same | |
| WO1990004412A1 (en) | Liposome immunoadjuvants containing il-2 | |
| US4148876A (en) | Biological preparations | |
| AU2013208693B2 (en) | Compositions and methods for treating viral infections | |
| IE910268A1 (en) | Liposome-containing intranasal vaccine formulation | |
| CA1079634A (en) | Antigens bound to exterior surface of microvesicles | |
| BR9609882A (pt) | Vacina processos para preparar a mesma para tratar uma doença infecciosa para inserir uma molécula de ácido nucleico em uma célula de marcaç o para administrar um agente terapêutico a um hospedeiro e para triar um antígeno imunogênico de um patógeno uso de uma vesícula de membrana composição farmacêutica sistema de liberação de drogas e vesícula de membrana | |
| US20110177163A1 (en) | Compositions and methods for treating hepatitis a | |
| Machluf et al. | Enhancing the immunogenicity of liposomal hepatitis B surface antigen (HBsAg) by controlling its delivery from polymeric microspheres | |
| Gregoriadis et al. | Liposomes enhance the immunogenicity of reconstituted influenza virus A/PR/8 envelopes and the formation of protective antibody by influenza virus A/Sichuan/87 (H3N2) surface antigen | |
| Kramp et al. | Liposomal enhancement of the immunogenicity of adenovirus type 5 hexon and fiber vaccines | |
| Gregoriadis | Liposomes as immunological adjuvants | |
| JP2003516936A5 (https=) | ||
| EP1764369A1 (de) | Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants | |
| Tan | A study of the efficacy of liposomes in comparison to new and established adjuvants in potentiating the antibody response against hepatitis B virus surface antigen | |
| CA1334165C (en) | Affinity associated vaccine | |
| Iwarson | Vaccination against hepatitis B | |
| WO2008001108A2 (en) | Silicon adjuvant |